Hepatitis virus entry inhibitor and pharmaceutical composition for treating hepatitis
WO2019009759A1
Combined medicinal preparation for treating viral infections
US2019233409A1
Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for use thereof
US2019382428A1
Prodrug of an HCV NS5B polymerase inhibitor and method of production and application thereof
US2019374557A1
Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
US2018099989A1
Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
US2018030080A1
Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use
WO2016130043A1
Benzo[1,2,4]thiadiazine inhibitors of hepatitis b virus replication and pharmaceutical composition for treating hepatitis b
US2017066746A1
Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods
AU2014221468A1
Substituted (R)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-enecarboxylic acid (variants) and ester thereof, method for producing and using same
US2013252992A1
Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof
